Response to pegylated interferon in a COVID‐19–positive elderly woman with primary myelofibrosis treated with ruxolitinib

• Published in: Clinical case reports Vol. 9; no. 4; pp. 2228 - 2235
• Main Authors: Frankel, Arthur E., Reddy, Renuka, DeSuza, Kayla R., Deeb, Khaled, Carlin, Aaron F., Smith, Davey, Xie, Yushuang, Naik, Eknath, Silver, Richard T., Hasselbalch, Hans C.
• Format: Journal Article
• Language: English
• Published: England John Wiley & Sons, Inc 01-04-2021; John Wiley and Sons Inc; Wiley
• Subjects: Asymptomatic; Bacterial infections; Case Report; Case Reports; COVID‐19; Cytokine storm; Disease; Genes; Infections; Interferon; Kinases; Mutation; Pathogenesis; ruxolitinib; Signal transduction; Stem cells; Tumor necrosis factor-TNF; Tumors; Viruses; COVID‐19; interferon; ruxolitinib
• ISSN: 2050-0904; 2050-0904
• DOI: 10.1002/ccr3.3997

An 83‐year‐old female had asymptomatic SARS‐CoV‐2 infection while taking ruxolitinib. She remained RT‐PCR positive for viral RNA for >120 days, and Pegylated interferon for 4 weeks led to viral RNA clearance. The observations support combination therapy of ruxolitinib + interferon for COVID‐19.
An 83‐year‐old female had asymptomatic SARS‐CoV‐2 infection while taking ruxolitinib. She remained RT‐PCR positive for viral RNA for > 120 days, and Pegylated interferon for 4 weeks led to viral RNA clearance. The observations support combination therapy of ruxolitinib + interferon for COVID‐19.